HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus.

AbstractOBJECTIVE:
To evaluate the single dose pharmacokinetics of an intravenous dose of lorazepam in pediatric patients treated for status epilepticus (SE) or with a history of SE.
STUDY DESIGN:
Ten hospitals in the Pediatric Emergency Care Applied Research Network enlisted patients 3 months to 17 years with convulsive SE (status cohort) or for a traditional pharmacokinetics study (elective cohort). Sparse sampling was used for the status cohort, and intensive sampling was used for the elective cohort. Non-compartmental analyses were performed on the elective cohort, and served to nest compartmental population pharmacokinetics analysis for both cohorts.
RESULTS:
A total of 48 patients in the status cohort and 15 patients in the elective cohort were enrolled. Median age was 7 years, 2 months. The population pharmacokinetics parameters were: clearance, 1.2 mL/min/kg; half-life, 16.8 hours; and volume of distribution, 1.5 L/kg. On the basis of the pharmacokinetics model, a 0.1 mg/kg dose is expected to achieve concentrations of approximately 100 ng/mL and maintain concentrations >30 to 50 ng/mL for 6 to 12 hours. A second dose of 0.05 mg/kg would achieve desired therapeutic serum levels for approximately 12 hours without excessive sedation. Age-dependent dosing is not necessary beyond using a maximum initial dose of 4 mg.
CONCLUSIONS:
Lorazepam pharmacokinetics in convulsive SE is similar to earlier pharmacokinetics measured in pediatric patients with cancer, except for longer half-life, and similar to adult pharmacokinetics parameters except for increased clearance.
AuthorsJames M Chamberlain, Edmund V Capparelli, Kathleen M Brown, Cheryl W Vance, Kathleen Lillis, Prashant Mahajan, Richard Lichenstein, Rachel M Stanley, Colleen O Davis, Stephen Gordon, Jill M Baren, John N van den Anker, Pediatric Emergency Care Applied Research Network (PECARN)
JournalThe Journal of pediatrics (J Pediatr) Vol. 160 Issue 4 Pg. 667-672.e2 (Apr 2012) ISSN: 1097-6833 [Electronic] United States
PMID22050870 (Publication Type: Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)
CopyrightCopyright © 2012 Mosby, Inc. All rights reserved.
Chemical References
  • Lorazepam
Topics
  • Adolescent
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Infusions, Intravenous
  • Lorazepam (administration & dosage, pharmacokinetics)
  • Prospective Studies
  • Status Epilepticus (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: